Monitoring Erythropoietin Therapy for Anaemia of Chronic Renal Failure by Serum Erythropoietin Assays

Marsden, J T; Sherwood, R.; Hillis, A. N.; Peters, T J

doi:10.1177/000456329303000219

Cited by 4 publications

(3 citation statements)

References 4 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum EPO levels are usually inappropriately low in patients with end-stage renal failure due to underproduction of EPO by the kidney. Treatment with recombinant human erythropoietin can correct the anemia in these patients, but due to the expense of the drug and the potential for hypertension and/or thrombosis, close monitoring of serum EPO levels is indicated (5).…”

mentioning

confidence: 99%

New automated chemiluminescent assay for erythropoietin

Benson

Hardy

Chaffin

et al. 2000

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

Erythropoietin (EPO) is a polypeptide hormone produced by the kidney that regulates erythropoiesis by controlling the proliferation and differentiation of erythroid progenitors in bone marrow. Assays for EPO are used to monitor dosage and response to human recombinant erythropoietin also may have diagnostic utility in the differential diagnosis of anemia and polycythemia. We evaluated an automated, chemiluminescent immunoassay for EPO (DPC Immulite) in terms of precision, linearity, interference, and correlation with reference assays. The Immulite assay demonstrated acceptable correlation with the reference immunochemiluminometric method (slope = 1.087, y intercept = 0.567, R value = 0.990). Within‐run CVs ranged from 2.3% to 5.0%, while between‐run CVs ranged from 4.1% to 9.5%. Linearity extended beyond the manufacturer’s stated claims, and recovery ranged from 96.8% to 100.9% across the concentrations tested. No significant interference was noted with hemoglobin, bilirubin, or triglyceride. Overall, this method compares favorably with the existing immunochemiluminometric reference method and offers clinical laboratories an alternative for the analysis of erythropoietin. J. Clin. Lab. Anal. 14:271–233, 2000. © 2000 Wiley‐Liss, Inc.

show abstract

mentioning

confidence: 99%

New automated chemiluminescent assay for erythropoietin

Benson

Hardy

Chaffin

et al. 2000

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

show abstract

“…There is considerable interest in the use of serum EPO concentrations in the differential diagnosis and monitoring of a variety of disease states, such as polycythaemia (Pearson & Messinezy, 1996) and anaemia of chronic disease (Miller et al. , 1990; Marsden et al. , 1993).…”

Section: Discussionmentioning

confidence: 99%

“…For most methods the normal reference range for serum EPO concentration is approximately 5-25 U/l determined in a population of healthy volunteers with normal haematology and free from any disease or other factors that may influence the values obtained, such as pregnancy, drugs and geographical location. There is considerable interest in the use of serum EPO concentrations in the differential diagnosis and monitoring of a variety of disease states, such as polycythaemia (Pearson & Messinezy, 1996) and anaemia of chronic disease (Miller et al, 1990;Marsden et al, 1993). Serum EPO concentrations can rise 100-to 1000-fold in patients with anaemia because of blood loss, iron deficiency or haemolysis.…”

Section: Discussionmentioning

confidence: 99%

A sample distribution programme for erythropoietin

Marsden

Day

Ellis

et al. 2006

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

A survey was sent to laboratories participating in the United Kingdom External Quality Assessment Service (UKNEQAS) Haematinics Scheme about the measurement of serum erythropoietin (EPO). Six laboratories, from a total of 120 that returned the survey, were measuring serum EPO concentrations by commercially available immunoassays on site in the United Kingdom. The workload of the laboratories varied from up to 100 specimens per month to more than 100 specimens analysed per week. All laboratories included control material in the assays and none of the laboratories was participating in an external quality assessment scheme for serum EPO. Four laboratories agreed to take part in the first sample distribution programme, with five and six laboratories participating in distributions 2 and 3 respectively. The results from eight kits were compared from the three distributions over a 2-year period. The serum EPO concentrations for the methods showed some variation across the range of 2.9-200 U/l when the serum EPO concentrations for each method were compared with the whole method mean. The results from this scheme have identified a role for an external quality assessment scheme for serum EPO measurements.

show abstract